Pfizer has entered into an agreement with Synthon to acquire exclusive commercialization rights to glatiramer acetate in the U.S. The drug is a potential generic version of Copaxone for the treatment of relapsing remitting multiple sclerosis. Synthon has filed an ANDA with the FDA for a once daily 20mg/ml formulation of glatiramer acetate, and an ANDA for a three times a week 40mg/ml formulation of glatiramer acetate. The 40mg/ml filing may be eligible for 180 days of shared marketing exclusi...